RTW Biotech Opportunities Ltd (LSE: RTWG), a closed-ended investment fund focused on biopharmaceutical and medical technology assets, has announced the repurchase of 350,000 ordinary shares at $2.43 per share on 18 November 2026. The bought-back shares will be held in treasury, reducing the total voting rights in the company to 316,839,823. The buyback was conducted under authority granted by shareholders at the company's Annual General Meeting in June 2026, with Jefferies International Limited acting as broker for the transaction.
Key Points
- RTW Biotech Opportunities Ltd (LSE: RTWG) — closed-ended investment fund managed by RTW Investments, LP
- The company repurchased 350,000 ordinary shares at $2.43 per share on 18 November 2026, to be held in treasury
- Total voting rights now stand at 316,839,823; issued share capital is 345,967,440 with 29,127,617 shares in treasury
- Investors should watch for further buyback activity ahead of the next AGM shareholder authority expected in 2027
350,000 Ordinary Shares Repurchased at $2.43 and Transferred to Treasury
RTW Biotech Opportunities Ltd confirmed it purchased 350,000 ordinary shares on 18 November 2026 at a price of $2.43 per share. Following settlement, the company's total issued ordinary share capital stands at 345,967,440 shares, of which 29,127,617 are now held in treasury and carry no voting rights. The company stated it is its current intention to continue holding any repurchased shares in treasury rather than cancelling them, a common approach among investment funds managing share capital structure.
June 2026 AGM Authority Permits Repurchase of Up to 14.99% of Ordinary Shares
The buyback was executed under a shareholder authority granted at the company's Annual General Meeting in June 2026, which permits RTW Biotech Opportunities to repurchase up to a maximum of 14.99% of its ordinary shares. The announcement states that the actual number of shares repurchased will depend on prevailing market conditions. This authority remains in force until the next shareholder authority is granted — expected at the 2027 Annual General Meeting — or until it is expressly revoked by shareholders. The company also confirmed it cannot pay a price that equates to a premium to net asset value.
316,839,823 Voting Rights Denominator Now Applicable Under FCA Disclosure Rules
Following the transaction, the company has confirmed that 316,839,823 represents the current denominator shareholders should use when calculating whether they are required to notify an interest, or a change to an interest, under the FCA's Disclosure and Transparency Rules. Jefferies International Limited has been instructed as broker for the company's buyback programme, an arrangement described in the announcement as being in accordance with FCA Listing Rules and the company's general repurchase authority.
RTW Investments, LP Manages the Fund's Focus on Biopharmaceutical and Medtech Assets
RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, described in the announcement as a healthcare-focused investment firm with scientific expertise and a track record of supporting life-sciences businesses. The fund targets transformative assets across the biopharmaceutical and medical technology sectors, investing in companies developing next-generation therapies and technologies. Investors may be watching future buyback disclosures as an indicator of ongoing capital management activity within the fund's existing AGM-approved framework.




Please wait processing your request...